Drug-induced liver injury (DILI) is a common toxicity observed in drug development and can lead to withdrawal of approved drugs from the market. To better understand the numerous mechanisms of DILI, recent efforts have focused on transporter inhibition, specifically liver canalicular bile salt export pump (Bsep) as one mechanism of DILI, and on the potential use of plasma bile acids as monitorable mechanism-based biomarkers of Bsep inhibition. To explore alternative mechanisms of bile acid increases in plasma, 6 antibiotic and 2 nonantibiotic drugs unlikely to be Bsep inhibitors were evaluated in rat studies. Surprisingly, all 6 antibiotics demonstrated 2-to 14-fold increases of plasma taurocholic acid (TCA). Also, unconjugated primary bile acids and secondary bile acids (both taurine-conjugated and unconjugated) were decreased in rat plasma after antibiotic treatments, but not with the nonantibiotic drugs. These results suggest alternative mechanisms of bile acids regulation such as attenuation of bacterial deconjugation of bile acids following reduction of gut microflora by antibiotics. Measurements of TCA transport in rat hepatocytes and Bsep-containing membrane vesicles suggest that inhibition of uptake into hepatocytes could also contribute to increases in plasma bile acid concentrations, while excluding inhibition of Bsep as a mechanism. These studies further demonstrate that there are several mechanisms that can lead to conjugated bile acid increases in plasma. By carefully considering the time course and magnitude of changes of individual bile acids relative to any changes seen in transaminases and bilirubin, interpretations and conclusions of the involvement of Bsep inhibition are enabled.
Drug-induced liver injury (DILI) is a common toxicity observed in drug development programs and can lead to withdrawal of approved drugs from the market or addition of a black-box warning in the drug labels. These drugs can be classified as hepatocellular or cholestatic, or mixed DILI. Antibiotics, anti-convulsants, and antidepressant therapies are among the most common agents that cause DILI in the Western Hemisphere (Hussaini and Farrington, 2014; Leitner et al., 2010; Robles et al., 2010; Stine and Lewis, 2013; Tailor et al., 2015) . Augmentin, isoniazid, nitrofurantoin, and fluoroquinolones are the most frequent causes of antibiotic-associated DILI (Hussaini and Farrington 2014) in the United States. In more severe cases, patients developed acute vanishing bile duct syndrome after taking antibiotic drugs such as amoxicillin, flucloxacillin, or azithromycin (Andrews and Daly, 2008; Davies et al., 1994; Juricic et al., 2010) .
Numerous mechanisms of DILI have been investigated in vitro, in in vivo animal models, or in human population studies to better understand and predict DILI in the clinic. These mechanisms include but are not limited to reactive metabolites (Lee et al., 2011; Tailor et al., 2015) , mitochondrial dysfunction (Aleo et al., 2014) , oxidative stress (Aleo et al., 2014) , immune activation (Tailor et al., 2015) , and transporter inhibition (Dawson et al., 2012; Morgan et al., 2010) . Recent efforts have focused on transporter inhibition, specifically liver canalicular bile salt export pump (BSEP) as one mechanism of DILI. Mutations in human BSEP can result in a condition known as progressive familial intrahepatic cholestasis type 2 (PFIC2) with severe health consequences in children (Varma et al., 2015) . These BSEP functional defects result in bile acid accumulation in hepatocytes, and hepatocellular damage. These findings support a causal association between liver injury and functional impairment of BSEP, and support the need to identify BSEP inhibition early in drug development to reduce the risk of DILI.
In drug discovery, several pharmaceutical companies are now screening drug candidates for their ability to inhibit BSEP in human (BSEP) and rat (Bsep) in vitro systems to better understand and predict human DILI caused or contributed by transporter inhibition. In vitro inhibition of BSEP has been shown to correlate with the risk of cholestatic DILI in humans (Dawson et al., 2012; Morgan et al., 2010 Morgan et al., , 2013 Thompson et al., 2012) , although the causality of such correlation has not been demonstrated in all cases. Initially, BSEP inhibition IC 50 cutoff values were used for ranking BSEP inhibition potential, followed by consideration of dose and exposure levels at steady state concentration (C ss ) or unbound plasma concentration (C max,u ) (Dawson et al., 2012; Morgan et al., 2010 Morgan et al., , 2013 Thompson et al., 2012) . Increased conjugated bile acids in plasma as a result of Bsep inhibition are potential monitorable mechanism-based biomarkers of Bsep inhibition in vivo. Furthermore, conjugated bile acids can be monitored in clinical serum or plasma samples when blood is taken for drug levels or serum clinical chemistry, making them an attractive biomarker to inform potential BSEP inhibition.
In addition to Bsep inhibition, there are other potential factors that may also result in plasma bile acid increases including inhibition of the hepatic uptake transporters, Sodium Taurocholate Cotransporting Polypeptide (Ntcp) and Organic Anion Transporting Polypeptides (Oatps), activation of bile acid synthesis pathways, and inhibition of Apical sodium-dependent bile acid transporter (Asbt) and organic solute transporters (Osta/b) in the intestine (Ballatori et al., 2005; Rodrigues et al., 2014) . The Ntcp transporter is mainly responsible for conjugated bile acid uptake to liver while the Oatp transporters are believed to be responsible for unconjugated bile acid uptake (Klaassen and Cui, 2015) .
In addition to these mechanisms, reports have indicated that gut bacteria are involved in bile acid metabolism including amino acid and sulfate deconjugation of conjugated bile acids, and 7a/b-dehydroxylation during enterohepatic recirculation (EHR) (Klaassen and Cui, 2015; Rodrigues et al., 2014; Swann et al., 2011) . Therefore, antibiotic drugs perturb gut bacteria and can subsequently affect bile acid homeostasis. To better understand how antibiotics may elevate plasma bile acids through a mechanism other than Bsep inhibition, several antibiotics were evaluated in rats and their effects on bile acid concentrations in plasma are presented here. In addition, we conducted in vitro transporter studies to assess the effect of one of the antibiotics, clarithromycin, on taurocholate transport.
MATERIALS AND METHODS

Chemicals and Reagents
Amoxicillin (AMX) and Erythromycin (ETM) were purchased from Sigma-Aldrich (St. Louis, MO) with purity >98%. Azithromycin (ATM) was obtained from Allichem LLC (Baltimore, MD) with purity >99%. Clarithromycin (CTM) was purchased from TCI America (Portlan, OR) with purity >99%. Flucloxacillin (FCX) and Tolcapone (TCP) were obtained from Toronto research chemicals Inc. (ON, Canada) . Telithromycin (TTM) and Entacapone (ECP) were purchased from Bosche Scientific (New Brunswick, NJ) with purity of greater than 97% and 98%, respectively.
Most of individual bile acids and 6 of 2,2,4,4-d4 stable isotope labeled internal standards (IS) as listed in Table 1 were purchased from Sigma-Aldrich (St. Louis, MO). Exceptions were noted as follows: Glycodeoxycholic acid (GDCA), and a and b tauromuricholic acid (TaMCA, TbMCA) were obtained from Steroid, Inc. (Newport, RI) and Taurocholic acid, 2,2 0 ,4,4 0 -d4 (TCA-d4) was purchased from Alsachim Inc. (Wilmington, DE) . The purity of these bile acids was > 98%. HPLC grade water with 0.1% formic acid, methanol, acetonitrile with 0.1% formic acid were purchased from Burdick & Jackson (Muskegon, MI). Charcoal stripped serum was obtained from Sigma-Aldrich (St. Louis, MO).
In Vivo 5-Day Rat Studies
Rat toxicity studies were designed and conducted with 6 antibiotic drugs and 2 nonantibiotic drugs to evaluate plasma bile acid profiles. All of these studies ( Blood samples were collected at 24 h postdose on study day 2 (after 1 dose) and study day 5 (after 4 doses), except in amoxicillin and flucloxacillin studies where blood samples were collected only on study day 5. Animals were fasted overnight prior to necropsies on study days 2 and 5, and approximately 2 mL of blood were collected from the vena cava in a serum separator tube and approximately 2 mL of blood were collected in EDTA tubes for isolating plasma. The processed samples were used for assessment of serum biochemical parameters and plasma bile acid levels. Serum clinical chemistry parameters were measured using a clinical chemistry analyzer (Beckman Coulter, Brea, CA). Plasma samples collected for subsequent bile acid analysis were stored at À70 C.
Plasma Sample Preparation for LC-MS/MS Analysis of Bile Acids
Plasma samples (50 mL) were processed with the addition of 20 mL of 6 deuterated (d4) internal standard (IS) mixture in 96-well plates. About 250 mL of acetonitrile with 0.1% formic acid were added into each well to precipitate protein. After a 15 min centrifugation, 200 mL of the supernatant were transferred to an Ostro plate (Waters Co.) to remove phospholipids. Eluants were dried and reconstituted in 1:1 in methanol:0.1% formic acid water. 10-point standard curves and 3 quality control (QC) samples were prepared in charcoal stripped serum. The concentrations in the standard curve ranged from 4 ng/mL to 4000 ng/mL. The QC concentrations were 20, 200, and 2000 ng/mL. 10 mL of processed plasma samples were then injected into the LC-MS system.
LC-MS/MS Conditions for Bile Acid Analysis
The LC-MS/MS conditions for bile acid analysis are summarized in Table 1 . An Acquity UPLC (Waters Co) was interfaced with AB Sciex 4000 MS system. Mobile phase A was 0.1% formic acid (FA) water and mobile phase B was acetonitrile (ACN) with 0.1% formic acid (FA). Gradient chromatographic separation of bile acids was performed on a 100 mm Â 1.0 mm (id) Acquity BEH C18 column with particle size of 1.7 mm. A gradient elution was performed with 15%B for 1 min, a linear increase to 50%B until 8 min, followed by an increase to 95%B from 8 min to 11 min, and held for 1 min. Then, reequilibration started from 12.01 min to 15 min. The flow rate was 0.1 mL/min. The MS turbo ion spray source was operated in the negative ion mode using the following settings: ion spray voltage ¼ À4000 V; ion sources heater temperature ¼ 450 C; source gas 1 ¼ 50 psi, source gas 2 ¼ 50 psi; and curtain gas ¼ 10 psi. Bile acids were monitored in the multiple reaction monitoring (MRM). Mass transitions and MS parameters are shown in Table 1 . Quadrupoles Q1 and Q3 were operated at unit resolution. The lower limit of quantification for all bile acids was 4 ng/mL.
Statistical Analysis of Bile Acid Data
Values below the lower limit of quantification (LLOQ) were replaced by the LLOQ limit. One way analysis of variance (ANOVA) models were fit separately to each bile acid response for each study day and each drug after natural log transformation. The ANOVA model included treatment group as a fixed factor. Differences between each dose group and concurrent control were estimated and tested from this model with the use of linear contrasts. Treatment effect size is reported as mean fold difference from concurrent vehicle response. P-values were not corrected for multiplicity.
In Vitro Bile Acid Transporter Inhibition Assay
The inhibitory effect of the test compound on ATP-dependent [ 3 H]TCA (1 mM, Perkin Elmer Life Sciences, Boston, MA) uptake was conducted in membrane vesicles isolated from baculovirus infected Spodoptera frugiperda (Sf9) cells containing rat Bsep (Abcb11) (Invitrogen Life Technologies, Carlsbad, CA) essentially as described previously (Prueksaritanont et al., 2014) . The experiment was performed in triplicate. Bsep-mediated [ 3 H]TCA uptake was calculated by subtracting the uptake of [ 3 H]TCA in the presence of AMP from that in the presence of ATP, and data were normalized to % control, where uptake in the absence of test compound was 100%. The IC 50 values for inhibition of Bsepmediated uptake were obtained by fitting the data to the formula below by nonlinear regression analysis using GraphPad Prism.
Where "control (%)" represents Bsep-mediated uptake measured in the presence of various concentrations of inhibitor to that in the absence of inhibitor and "I" represents nominal inhibitor concentration.
Inhibition of Intrinsic In Vitro Biliary Clearance and Biliary Excretion Index in Rat HepatoPac
The Taurocholic acid (TCA) transport was calculated by subtracting the accumulation in stromal only cultures from the accumulation in HepatoPac cultures. The in vitro Cl biliary represents both uptake of TCA across the sinusoidal membrane into the hepatocyte as well as its efflux across the canalicular membrane into the bile canaliculi. The BEI represents the percent of accumulated TCA that resides in the bile canaliculi (i.e., efflux across the canalicular membrane; Wolf et al., 2010) . Inhibition of in vitro Cl biliary with no change in BEI suggests that the uptake of TCA is inhibited by the test compound, while inhibition of both in vitro Cl biliary and BEI suggests that both uptake and efflux pathways of TCA are inhibited. Cyclosporin A (10 lM; positive control inhibitor) inhibited the in vitro Cl biliary (IC 50 ¼ 1.9 lM) and BEI (IC 50 ¼ 3.8 lM) of TCA, confirming the functionality of the assay (data not shown). Additional details on the in vitro methodology can be found in Supplementary data, Supplemental Methods.
Uptake Studies in Cryopreserved Rat Hepatocytes
Wistar-Hanover knockout rats lacking expression of Oatp1b2, -1a1, and -1a4 were generated using Zn-finger technology at Merck & Co., Inc. (Kenilworth, NJ, USA). A detailed description and phenotypic characterization of these rats will be described elsewhere (Yabut et al., in preparation). Cryopreserved hepatocytes from wild type (WT) and knockout (KO) Oatp rats were prepared (Bioreclamation, LLC). Uptake studies with [ 3 H]TCA
(1 mM; Perkin Elmer Life Sciences, Boston, MA) were conducted essentially as described in Prueksaritanont et al. (2014) . Each experiment was performed in triplicate.
RESULTS
In Vivo Clinical Chemistry Parameters and Histomorphology Findings
Standard serum clinical chemistry parameters were measured on study days 2 and 5. Liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were not increased in the studies, except following azithromycin treatment. In the azithromycin study, 1 of 4 rats at each dose group (400 mkd or 600 mkd, PO) showed an increase in ALT and AST. ALT levels in these rats were approximately 7-fold (400 mkd) or 4-fold (600 mkd) over concurrent control mean values, while AST levels were 7-fold (400 mkd) or 3-fold (600 mkd) over concurrent control mean values on study day 5. All rats survived to the scheduled necropsy. Test articlerelated histomorphologic changes in liver were not observed, with the exception of azithromycin treatment. The main azithromycin-related change was observed on tissues taken on study day 5 and consisted of very slight to slight vacuolation in liver, especially in the centrilobular area and bile duct. Single cell necrosis was observed in 3 of 4 rats given 600 mkd and none in rats given 400 mkd azithromycin.
Plasma Bile Acid Profiles in Rats Treated With Antibiotics
Ten bile acids were evaluated in plasma using LC-MS/MS. Plasma bile acid profiles revealed that each individual antibiotic had prominent effects on individual bile acids. Each individual bile acid from each animal in the treatment groups was compared with the concurrent control and statistical results for each antibiotic were summarized in Table 3 . Bile acid changes were color coded to reflect an increase or decrease pattern in the table. In the plasma samples from animals treated with antibiotics, significantly increased taurine conjugated primary bile acids, TCA, TCDCA, and TMCA either in the high dose (H) group or in both low (L) and high dose groups were observed (Table 3) . However, after telithromycin treatment, only TCA increase in plasma was observed. As shown in Table 3 , all 6 antibiotic treatments significantly decreased unconjugated bile acids (CA, CDCA, and DCA) and glycine conjugated bile acids (GCDCA, GDCA), especially on study day 5. Only azithromycin and telithromycin significantly decreased GCA. The secondary bile acid DCA and its glycine conjugated form, were decreased in all antibiotic treated groups, while the taurine conjugated form TDCA, decreased only from the 2 b-lactam antibiotics, not the 4 macrolide antibiotics (Table 3 ). Figure 1 presents the concentrations of selected bile acids, TCA, TCDCA, CA, and CDCA from each antibiotic treatment.
Ratios of treated versus vehicle control groups for each bile acid and each antibiotic are presented in Table 4 . The significant increases of TCA in plasma at 24 h postdose ranged from 2-fold to 14-fold over concurrent vehicle control. The significant decreases of CA were 0.01-to 0.08-fold below concurrent vehicle control. Two nonantibiotic drugs, tolcapone and entacapone, were also evaluated to determine the specificity of the bile acid changes observed with antibiotic treatments. Fold changes of each plasma bile acid in each nonantibiotic treatment group are presented in Table 5 . Figure 2 shows the concentrations of selected bile acids, TCA, TCDCA, CA, and CDCA after the 2 nonantibiotic treatments. With both tolcapone and entacapone treatment, no clear increase or decrease in plasma bile acids were observed, contrasting what was observed after antibiotic treatments. However, there was a clear increase of GCDCA with Entacapone treatment at 400 mg/kg/day dose as listed in Table  5 . Together, these data demonstrate that the changes in bile acid patterns were specific to antibiotic treatments, and not observed with nonantibiotic treatments.
In Vitro Bsep Inhibition
To assess whether inhibition of Bsep could lead to increases in TCA levels in rat, compounds tested in vivo were screened for their potential to inhibit the transport of [ 3 H]TCA uptake into membrane vesicles containing rat Bsep. The Bsep IC 50 was found to be >25 mM for all antibiotic drugs tested except for telithromycin, which showed an estimated IC 50 of 18 mM (Table  2) . Tolcapone and entacapone, the 2 non-antibiotic drugs tested, did not significantly inhibit Bsep at 25 mM, the maximum concentration tested.
In Vitro Bile Salt Transport Inhibition in Hepatocytes
While Ntcp has been shown to mediate the uptake of TCA into the hepatocyte (Rodrigues et al., 2014) , the relative contribution of Oatp to TCA uptake in rat is not known. To assess whether inhibition of Oatp could contribute to the increased plasma TCA levels observed in rats treated with clarithromycin, we examined the uptake of [ 3 H]TCA into WT and Oatp1a1/1a4/1b2 KO rat hepatocytes in vitro in the presence and absence of sodium ( Figure 3) . As expected, a sodium and time dependent increase of [ 3 H]TCA was observed in WT rat hepatocytes. Relative to the control [wild type (þNa)], uptake was reduced by $1.3-to 1.6-fold in Oatps KO hepatocytes in the presence of sodium and by $2.4-to 3-fold in WT hepatocytes in the absence of sodium at 1 min in 2 independent studies. This most likely was not explained by a lower expression of Ntcp in the KO hepatocytes as mRNA levels for this transporter were similar in livers from WT versus KO rats (data not shown). Clarithromycin was chosen to assess whether drugmediated liver bile acid transporter inhibition could lead to increases in plasma TCA levels in rat. To assess whether clarithromycin inhibited the uptake and/or efflux of TCA in micropatterned rat hepatocytes, we examined the potential for clarithromycin to inhibit the intrinsic in vitro biliary clearance (in vitro Cl biliary ) and the biliary excretion index (BEI) of TCA transport in rat HepatoPac (Figure 4) 
DISCUSSION
Increases in taurine conjugated primary bile acids and decreases of unconjugated bile acids in rat plasma after antibiotic treatments were observed in our studies. Secondary bile acids (unconjugated and conjugated) were decreased. Based on in vitro Bsep inhibition data, these antibiotics were shown not to inhibit Bsep at the concentrations tested, except telithromycin, suggesting a mechanism for bile acid increases independent of Bsep inhibition.
Antibiotic Treatments Reduce the Function of Gut Microbes to Deconjugate Bile Acids
Bile acids are synthesized in the liver from cholesterol, followed by conjugation with taurine or glycine by the enzyme, bile acidCoA:amino acid N-acyltransferase (BACAT) (O'Byrne et al., 2003) . These conjugated bile acids in hepatocytes are then transported by Bsep into the bile canalicular space, and released from the bile ducts directly into the upper small intestine due to the lack of a gallbladder in rats. A portion of these conjugated bile acids can be re-absorbed by passive diffusion, and remaining unabsorbed bile acids are actively transported in the ileum by Asbt. In the intestine, the taurine or glycine conjugated bile acids are deconjugated (deamidation) by gut bacteria by enzymes known as bile salt hydrolases (BSH). This occurs mainly in the mid to lower ileum and large intestine (Begley et al., 2006; Gilliland and Speck 1977; Ridlon et al., 2006; Rodrigues et al., 2014) . Specific strains of intestinal bacteria that are capable of deconjugation were reported and summarized by Midtvedt (1974) and Shimada et al. (1969) , and are mostly gram positive bacteria. Most BSHs are more efficient at hydrolyzing glycoconjugated bile acids than tauroconjugated bile acids (Begley et al., 2006) . This may explain the protective mechanism of BSHs because glycolconjugated bile acids are extremely toxic at acidic pH. Our findings of increased taurine conjugated bile acids, but not glycine conjugated bile acids after antibiotic treatment are in agreement with results from Begley et al. (2006) .
Oral administration of antibiotics in rats may reach high enough exposure to reduce or deplete the deconjugation function of gut microbes, which is consistent with the detected increase in conjugated primary bile acids and corresponding decrease in unconjugated bile acids in plasma in antibiotic treated relative to the vehicle control groups. In fact, the bile acid profiles seen in our studies are in agreement with the plasma bile acid profiles in germ-free rats (Swann et al., 2011) or mice (Sayin et al., 2013; Selwyn et al., 2015) . However, continuous administration of antibiotics in drinking water may not reach Zhang et al. (2014) that several individual antibiotics administered in drinking water did not produce bile acid changes in C57BL/6 mice. Furthermore, direct evidence of attenuated deconjugation in the intestinal lumen from C57BL6 mice orally dosed with ampicillin at 100 mg/kg/day for 3 days was reported (Kuribayashi et al., 2012) . Increases of TCA and TMCA, and decreases of CA and bMCA in intestinal lumen were observed in antibiotic treated mice (Kuribayashi et al., 2012) or germ-free mice (Sayin et al., 2013) . However, little information was reported on glycine conjugated bile acids, most likely because of low levels and/or no changes.
Antibiotic Treatments Decrease or Deplete Metabolism of Primary Bile Acids Into Secondary Bile Acids in the Guts
CA and a-/b-MCA are the major primary bile acids in rats and their secondary bile acids are DCA and xMCA, respectively. CDCA is a minor primary bile acid in rats and its secondary bile acid is LCA. The metabolism of CDCA to aMCA, further to bMCA in rat liver was reported by Botham and Boyd (1983) . Thus, aMCA and bMCA are considered primary bile acids in rats besides CA and CDCA. Secondary bile acids are those biotransformed by intestinal microbes that are capable of 7a/bdehydroxylation of bile acids (Ridlon et al., 2006; Ridlon and Hylemon 2012) . Antibiotic treatments decrease or deplete the function of gut microbes to metabolize the primary bile acids into secondary bile acids in the gut (Samuel et al., 1973; Theriot et al., 2016) . Due to low concentrations of LCA and no xMCA standard, we only analyzed plasma DCA and observed a decrease of DCA in rat plasma in treated over group groups. This Tables 1 and 2 for abbreviated names). observation is in agreement with germ-free rats (Swann et al., 2011) , and human plasma data after 500 mg of vancomycin treatment for 7 days (Vrieze et al., 2014) . Similar findings were reported by Zhang et al. (2014) where plasma DCA and TDCA were decreased in mice treated with a combination of 2 antibiotics. Also, direct evidences of decreased DCA were reported in rat feces after erythromycin treatment (Gustafsson et al., 1977) , and after latamoxef or cefotaxime treatment (Hashimoto et al., 1996) .
Other Factors That Can Result in Elevation of Taurine Conjugated Bile Acids in Rat Plasma
Besides reduction of gut microbes by antibiotics, additional factors including liver necrosis (including cholestasis), inhibition of uptake transporters (esp. Ntcp and Oatps), increased bile acid synthesis, and Bsep inhibition (including possible metabolitemediated Bsep inhibition) can result in the elevation of taurine conjugated bile acids in plasma. Luo et al. (2014) reported an increase of serum TCA and liver necrosis in rats when the liver toxicants Galactosamine, microcystin-LR, a-naphthylisocyanate, and acetaminophen were administered. Additionally, GCA and CA were also increased with hepatocellular necrosis. Also, Yamazaki et al. (2013) reported either increases of glycine conjugated or taurine conjugated bile acids, or increases of both by hepatotoxins. Similarly, conjugated bile acids were increased in patients with acetaminophen-incduced acute liver failure (Woolbright et al., 2014) . Therefore, interpretation of these bile acid increases should be carefully examined with the temporal individual bile acid patterns, severity and time course of clinical chemistry, and histomorphological changes (necrosis and cholestasis). In our azithromycin rat study, because slight single cell necrosis was observed in high dose, plasma taurine conjugated bile acid increase may also be partially contributed by a potential leakage to a lesser extent because we did not observe increase in unconjugated bile acids. A decrease of unconjugated bile acids following antibiotic treatment may be useful in differentiating the mechanism of bile acid increases from that of hepatotoxins. Inhibition of uptake transporters Ntcp or Oatps may also contribute to conjugated bile acid increases in plasma because dose levels in our studies were high. Consistent with the fact that Ntcp is generally considered as the major uptake transporter for TCA in hepatocytes (Meier and Stieger, 2002) , our in vitro data suggest that in rats the relative contribution of Oatp1a1/1a4/ 1b2 to uptake of TCA is low ($30 to 40%). Blocking this process would therefore result in an approximate 1.4-to 1.7-fold increase in TCA levels in plasma (Zamek-Gliszczynski et al., 2009 ). Therefore, Oatps will not contribute significantly to the effects observed in this paper. We were unable to assess the relative contribution of each Oatp individually as hepatocytes from single Oatp knockout rats were not available. To what extent the findings in vitro are relevant in vivo requires further investigation. Plasma TCA levels were not increased in Oatp1a1/1a4/1b2 KO rats compared to controls (data not shown); this discrepancy between in vitro and in vivo could be explained by compensatory mechanisms in TCA synthesis and disposition in KO rats. Further, acute effects of an Oatp inhibitor may not manifest in significant differences in plasma TCA levels at steady state in vivo. Recently, it was shown that in humans OATP1B may play a role in the uptake of some conjugated bile salts (Yee et al., 2016) .
Studies in micropatterned rat hepatocyte co-cultures demonstrated that clarithromycin did inhibit uptake of TCA in hepatocytes, whereas transport into the canalicular space was not affected. The IC 50 for inhibition of uptake was high (47 lM), but estimated drug exposure data from our study in rats indicated that the in vivo unbound concentration at the inlet of the liver [calculated as in Hirano et al., (2006) ] exceeded the IC 50 (data not shown). No potential inhibition of uptake transporters in sandwich-cultured rat and human hepatocytes were reported for amoxicillin at 220 lM (Wolf et al., 2010) . However, 11 antibiotics other than the 6 we studied were tested and 5 of those had potential to inhibit uptake transporters with nafcillin showing the strongest inhibition ($57% of the control at 80 lM) (Wolf et al., 2010) . Furthermore, NTCP deficiency in patients can cause extremely high levels of conjugated bile acids in plasma (Vaz et al., 2015) without clinical signs of cholestatic jaundice or liver damage. This confirms that NTCP plays a major role in transporting conjugated bile acids from plasma into the hepatocytes. However, there is likely no association of NTCP inhibition with DILI risk (Dong et al., 2015) . Besides NTCP inhibition or deficiency, increases of taurine conjugated bile acids may be in part contributed by increased bile acid synthesis in liver as supported by upregulated hepatic CYP7A1 (a major bile acid synthesis enzyme) mRNA expression after ampicillin treatment in mice (Miyata et al., 2009 (Miyata et al., , 2011 . Increased TCA and TbMCA in liver were also observed in ampicillin treated mice. 
CONCLUSION
Conjugated bile acids in plasma can be evaluated as monitorable biomarkers to inform on potential Bsep inhibition and ultimately liver injury (Watanabe et al., 2015) . However, in addition to increases of conjugated bile acids resulting from BSEP/Bsep inhibition, alternative mechanisms independent of BSEP/Bsep inhibition may also result in plasma bile acid increases. Here, several antibiotics determined not to be Bsep inhibitors were shown to significantly increase plasma TCA concentrations (2-to 14-fold) after antibiotic treatments in rats. These results are consistent with an alternative mechanism involving attenuation of bacterial deconjugation of bile acids following reduction of gut microflora by antibiotics, and possibly contribution from inhibition of uptake of bile salts into hepatocytes. The decreases of primary unconjugated bile acids and secondary bile acids in plasma are a signature of antibiotic effects not involving Bsep/ Ntcp inhibition.
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